New Protein LAPTM5 Worsens Skin Inflammation in Rosacea by Stabilizing STING
Background
Rosacea is a chronic inflammatory skin condition characterized by redness, visible blood vessels, and papules. The innate immune system, particularly the STING (STimulator of INterferon Genes) pathway, is increasingly recognized as a key driver of this inflammation, often triggered by antimicrobial peptides like LL-37. While STING activation is known to contribute to rosacea pathogenesis, the precise role of LAPTM5 in modulating STING-mediated inflammation in this context has been unclear.
Results
The researchers found that LAPTM5 significantly exacerbates STING-mediated inflammation. Overexpression of LAPTM5 led to a substantial increase in STING protein levels, preventing its degradation and amplifying downstream inflammatory signaling. Specifically, in LL-37-stimulated cells, LAPTM5 overexpression resulted in a 2.5-fold increase in IL-6 and a 3-fold increase in TNF-α compared to control cells. Conversely, genetic knockdown of LAPTM5 significantly attenuated the inflammatory response, leading to a 40% decrease in LL-37-induced inflammatory cytokine secretion. This suggests a direct regulatory role. > LAPTM5 directly stabilizes the STING protein, preventing its degradation and thereby amplifying the inflammatory cascade in response to LL-37, a key trigger in rosacea.
Why It Matters
This research identifies LAPTM5 as a novel and critical regulator of the STING pathway in the context of rosacea, offering a new perspective on the disease's pathogenesis. The findings suggest that targeting LAPTM5 could represent a promising therapeutic strategy to mitigate chronic skin inflammation in rosacea patients. Future work will focus on developing specific LAPTM5 inhibitors and testing their efficacy in preclinical models, potentially paving the way for human clinical trials.